CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 135 enrolled
Drug / intervention
Variation in eye pressure response to timolol and latanoprost treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01677507
NCT01677507Phase 4Completed

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

University of Michigan·interventional·Posted Sep 3, 2012·Updated Sep 13, 2017

In Brief

A Phase 4 clinical trial evaluating Variation in eye pressure response to timolol and latanoprost treatment for Glaucoma and Healthy. Completed, enrolled 135 participants across 3 sites.

Detailed Summary

Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive factors for drug response. Our long-term goal is to improve outcomes by identifying biomarkers and environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of disease progression, "poor response" to treatment, and large IOP fluctuation. Our purpose of this research project is to address this critical barrier by focusing on physiological factors that predict IOP response to drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Healthy
CountriesUnited States

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 3, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 30, 2016
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 13.8 years ago

Interventions

Variation in eye pressure response to timolol and latanoprost treatmentdrug

Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.